Lipenan

Atorvastatin/Ezetimibe, the active ingredients in Lipenan, are HMG‑CoA reductase inhibitor and cholesterol absorption inhibitor presented as oral tablets for oral use. They are prescribed to lower elevated cholesterol and triglyceride levels in adults with specific lipid disorders.

GNH USA supplies Lipenan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipenan addresses lipid abnormalities by targeting cholesterol synthesis and absorption.

- Hypercholesterolemia: reduces low‑density lipoprotein cholesterol (LDL‑C) levels. - Mixed dyslipidemia: lowers total cholesterol, LDL‑C and triglycerides while modestly raising HDL‑C. - Familial hypercholesterolemia: improves lipid profile in genetically high‑cholesterol patients.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Abdominal pain: discomfort in the stomach area. - Diarrhea: loose stools. - Nausea: feeling of sickness. - Elevated liver enzymes: mild increases in ALT/AST.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with dark urine. - Acute liver injury: marked elevation of transaminases or jaundice. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Myopathy: muscle weakness with elevated CK. - Pancreatitis: abdominal pain with elevated pancreatic enzymes.

Before initiating therapy, consider the following precautions: - Liver function monitoring: assess baseline and periodic ALT/AST levels. - Renal impairment: evaluate kidney function and adjust if necessary. - Drug interaction review: check concomitant medications for potential interactions. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture.

Lipenan may interact with several medicines; awareness of the interaction severity is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase atorvastatin exposure. - Gemfibrozil: markedly raises risk of myopathy and rhabdomyolysis. - Potent CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce lipid‑lowering efficacy.

Moderate Interactions (Monitor Closely): - Antacids: may diminish ezetimibe absorption. - Warfarin: potential enhancement of anticoagulant effect. - Niacin: increased likelihood of hepatic toxicity.